Acutaas Chemicals, through its wholly owned subsidiary Acutaas Advance Material Limited, has completed the acquisition of a 75% controlling stake in South Korean firm Indichem Inc. Indichem is a newly incorporated entity specializing in the semiconductor chemicals industry, providing Acutaas with a strategic entry into this high-growth global market. The acquisition involved 300,000 shares at a par value of KRW 500 each plus a share premium. Indichem is currently constructing a manufacturing plant in South Korea, which is scheduled for commissioning by the end of the 2025 calendar year.

Acutaas Chemicals reported a stellar Q3 FY26 with revenue growing 43% YoY to ₹393.2 crores, driven by a 47% surge in the Advanced Pharma Intermediates segment. The company achieved its highest-ever margins, with EBITDA margins expanding significantly to 38.3% due to a favorable product mix and operating leverage. Management has upgraded its full-year FY26 revenue growth guidance to 30% and EBITDA margin guidance to a range of 32-35%. Strategic expansions into battery and semiconductor chemicals are progressing, with a new battery chemicals block inaugurated in January 2026.

Acutaas Chemicals Limited, formerly known as Ami Organics, has released its Annual Sustainability Report for FY 2024-25, reporting a standalone revenue of ₹9,898 million. The company achieved a significant 25% increase in production capacity, primarily driven by its Ankleshwar facility. Strategically, the firm is expanding into high-value sectors including semiconductor-grade chemistries and battery materials. On the ESG front, it earned the EcoVadis Platinum Medal, placing it in the top 1% of companies globally, and operationalized 15.8 MW of solar capacity.

Acutaas Chemicals (formerly Ami Organics) reported a stellar performance for Q3 FY26, with consolidated revenue growing 42.3% YoY to ₹391.2 crore. Net profit for the quarter witnessed a massive jump of 139% YoY, reaching ₹108.6 crore compared to ₹45.4 crore in the previous year. For the nine-month period, the company has already surpassed its full-year FY25 profit, recording ₹222.1 crore. The company also highlighted a strategic investment of ₹130.80 crore in its South Korean joint venture, Indichem Inc., to bolster its specialty chemicals portfolio.

Acutaas Chemicals reported a stellar performance for Q3 FY26, with revenue growing 43% YoY to ₹3,932 million. The company achieved a significant milestone as quarterly PAT crossed ₹1,000 million for the first time, reaching ₹1,062 million. Profitability margins saw substantial expansion, with EBITDA margins jumping to 38.3% from 25.0% in the previous year. Management has also raised its full-year revenue growth guidance from 25% to approximately 30%, citing strong momentum in the CDMO business and upcoming verticals like battery and semiconductor chemicals.

Acutaas Chemicals reported a stellar Q3 FY26 performance with revenue growing 43% YoY to ₹3,932 million, driven by a robust ramp-up in the CDMO business. Profitability saw a massive jump as EBITDA rose 119.4% to ₹1,507 million, with margins expanding significantly to 38.3% due to favorable product mix and operating leverage. Consequently, PAT grew by 133.7% YoY to reach ₹1,062 million, the highest ever for the company. Management has revised its full-year revenue growth guidance upward to approximately 30% based on a strong order book and improved visibility.

Acutaas Chemicals Limited has officially inaugurated Phase 1 of its new state-of-the-art manufacturing block at the Unit-III Jhagadia facility in Gujarat. This dedicated facility will focus on producing electrolyte additives and other battery chemicals, marking a significant expansion into the high-growth EV supply chain. The inauguration took place on January 19, 2026, following an initial project intimation in December 2024. This move aligns with the company's strategy to diversify its specialty chemical portfolio into the energy storage sector.